Breaking News Instant updates and real-time market news.

ADRO

Aduro Biotech

$7.90

-0.15 (-1.86%)

, VRNA

Verona Pharma

$20.00

0.01 (0.05%)

04:55
04/10/18
04/10
04:55
04/10/18
04:55

H.C. Wainwright to hold a conference

Global Life Sciences Conference is being held in Monaco on April 8-10.

ADRO

Aduro Biotech

$7.90

-0.15 (-1.86%)

VRNA

Verona Pharma

$20.00

0.01 (0.05%)

AKBA

Akebia

$9.47

-0.07 (-0.73%)

EIGR

Eiger BioPharmaceuticals

$9.80

0.7 (7.69%)

CDNA

CareDx

$8.72

0.19 (2.23%)

CNCE

Concert Pharmaceuticals

$20.04

1.03 (5.42%)

AUPH

Aurinia Pharmaceuticals

$5.16

0.01 (0.19%)

GBT

Global Blood Therapeutics

$43.80

2.15 (5.16%)

AVEO

Aveo Oncology

$2.50

0.2 (8.70%)

COLL

Collegium Pharmaceutical

$21.79

-0.02 (-0.09%)

PDLI

PDL BioPharma

$3.00

-0.02 (-0.66%)

  • 10

    Apr

  • 16

    Apr

  • 17

    Apr

  • 18

    Apr

  • 23

    Apr

  • 25

    Apr

  • 08

    May

  • 29

    May

  • 12

    Jun

ADRO Aduro Biotech
$7.90

-0.15 (-1.86%)

02/21/18
CANT
02/21/18
INITIATION
Target $15
CANT
Overweight
Aduro Biotech initiated with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald started Aduro Biotech with an Overweight rating and $15 price target.
02/22/18
CANT
02/22/18
INITIATION
Target $15
CANT
Overweight
Cantor likes Aduro's immuno-oncology pipeline, starts at Overweight
Cantor Fitzgerald analyst Mara Goldstein last night initiated Aduro Biotech with an Overweight rating and $15 price target. The analyst likes the company's "broad pipeline," which she believes has the potential to translate into large market opportunities based on several novel immuno-oncology candidates. She expects upcoming catalysts and milestones to expand Aduro's valuation.
02/22/18
02/22/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Loxo Oncology (LOXO) initiated with an Outperform at Oppenheimer. 2. Asterias (AST) initiated with a Buy at B. Riley FBR. 3. Viveve (VIVE) initiated with a Buy at Empire. 4. Panhandle Oil & Gas (PHX) initiated with a Buy at Roth Capital. 5. Aduro Biotech (ADRO) initiated with an Overweight at Cantor Fitzgerald. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
12/13/17
HCWC
12/13/17
NO CHANGE
Target $9.5
HCWC
Buy
Aduro Biotech price target lowered to $9.50 from $18 at H.C. Wainwright
H.C. Wainwright analyst Joseph Pantginis lowered his price target for Aduro Biotech to $9.50 after the company announced the termination of its three CRS-207 clinical studies and discontinuation of the program due to insufficient clinical activity. The analyst believes investors placed limited value to this program after the May 2016 failure of the Phase 2b study in pancreatic cancer. Aduro has a diverse set of candidates in the pipeline which it will place more focus on as a result of CRS-207 based programs being terminated, Pantginis tells investors in a research note. He keeps a Buy rating on Aduro.
VRNA Verona Pharma
$20.00

0.01 (0.05%)

05/22/17
05/22/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Alcoa (AA) initiated with a Buy at Clarksons Platou. 2. Floor & Decor (FND) was initiated with an Outperform at Credit Suisse, a Hold at Jefferies, a Neutral at Piper Jaffray, a Neutral at Goldman Sachs, and an Overweight at Barclays. 3. Verona Pharma (VRNA) was initiated with an Outperform at Wedbush, and a Buy at SunTrust and Stifel. 4. The Medicines Co. (MDCO) initiated with a Perform at Oppenheimer. 5. Dexcom (DXCM) assumed with an Overweight at Piper Jaffray. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
03/27/18
RHCO
03/27/18
NO CHANGE
Target $37
RHCO
Buy
Verona Pharma price target raised to $37 from $26 at SunTrust
SunTrust analyst Yatin Suneja raised his price target on Verona Pharma to $37 after the company's "highly favorable" phase 2b results for RPL 554 in COPD maintenance. The analyst raises his probability of success on the treatment to 40% from 33% and adjusts his model based on the data while also keeping his Buy rating on Verona Pharma.
03/27/18
WEDB
03/27/18
NO CHANGE
Target $55
WEDB
Outperform
Verona Pharma price target raised to $55 from $48 at Wedbush
Wedbush analyst Liana Moussatos raised her price target for Verona Pharma to $55 from $48 as statistically significant, clinically meaningful Phase 2b results for nebulized RPL554 maintenance therapy of COPD reinforce the clinical benefits of dual PDE3/PDE4 inhibition in respiratory diseases. The analyst reiterates an Outperform rating on the shares.
02/20/18
BREN
02/20/18
INITIATION
Target $30
BREN
Buy
Verona Pharma initiated with a Buy at Berenberg
Berenberg analyst Patrick Trucchio initiated Verona Pharma with a Buy and $30 price target.
AKBA Akebia
$9.47

-0.07 (-0.73%)

02/12/18
PIPR
02/12/18
NO CHANGE
PIPR
Overweight
Piper still positive on Akebia following vadadustat program updates
Piper Jaffray analyst Christopher Raymond said he still has a positive outlook on Akebia after the company confirmed the timing for its pivotal INNO2VATE and PRO2TECT Phase 3 trials and made updates on its additional FO2RWARD and TRILO2GY trials. He thinks those updates can provide commercial benefit globally and management said the trial changes do not change its cash guidance, noted Raymond, who keeps an Overweight rating on Akebia shares.
12/18/17
PIPR
12/18/17
INITIATION
Target $26
PIPR
Overweight
Akebia initiated with an Overweight at Piper Jaffray
Piper Jaffray analyst Christopher Raymond initiated Akebia (AKBA) with an Overweight rating and a price target of $26. The analyst cites the company's "combination of sound biology, clean safety, meaningful unmet medical need and an attractive relative valuation". While the near term prospects for Akebia revolve around first-to- market player Fibrogen (FGEN) in the HIF space, the analyst contends, Akebia can generate its own share of anemia market once its lead compound vadadustat is approved.
12/07/17
12/07/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Sogou (SOGO) initiated with an Overweight at JPMorgan. 2. Amag Pharmaceuticals (AMAG) initiated with a Neutral at B. Riley FBR. 3. Akebia (AKBA) initiated with a Buy at BTIG. 4. Synnex (SNX) initiated with a Buy at SunTrust. 5. Cancer Genetics (CGIX) initiated with a Buy at Maxim. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
12/07/17
BTIG
12/07/17
INITIATION
Target $30
BTIG
Buy
Akebia initiated with a Buy at BTIG
BTIG analyst Robert Hazlett initiated Akebia with a Buy rating and a price target of $30. Hazlett says the company's development of Vadadustat - an HIF-PH inhibitor for anemia secondary to chronic kidney disease - has the potential to attain "hemoglobin control with material advantages compared to current standard-of-care injectable erythropoiesis stimulating agents". With its development partnerships in Japan and EU, the treatment is in a Phase 3 program expected for readouts in the first half of 2019.
EIGR Eiger BioPharmaceuticals
$9.80

0.7 (7.69%)

01/16/18
JEFF
01/16/18
NO CHANGE
Target $26
JEFF
Buy
Eiger selloff on failed study an overreaction, says Jefferies
Jefferies analyst Maury Raycroft views the selloff today in shares of Eiger BioPharmaceuticals as an overreaction. The analyst notes that his model did not include pulmonary arterial hypertension, which failed this morning in a Phase II trial. He viewed the Liberty study as a "promising" with high reward potential, however. Nevertheless, Raycroft sees multiple near-term catalysts to drive Eiger shares. He reiterates a Buy rating on the stock with a $26 price target.
01/16/18
PIPR
01/16/18
NO CHANGE
Target $17
PIPR
Overweight
Eiger BioPharmaceuticals price target lowered to $17 from $35 at Piper Jaffray
Piper Jaffray analyst Edward Tenthoff cut his price target for Eiger BioPharmaceuticals to $17 from $35 after the Phase II Liberty study of ubenimex in pulmonary arterial hypertension failed to meet the primary and secondary endpoints. The stock in morning trading is down 44%, or $7.09, to $8.91.The analyst removed pulmonary arterial hypertension from this model but reiterates an Overweight rating on the shares for the rest of Eiger's orphan drug pipeline. The company will meet with the FDA to discuss a registrational path for Sarasar and pegylated interferon-lambda and likely start a Phase III trial by the end of 2018, Tenthoff tells investors in a research note.
03/21/18
PIPR
03/21/18
NO CHANGE
Target $17
PIPR
Overweight
Piper remains buyer of Eiger after FDA agrees to single Phase III trial
Piper Jaffray analyst Edward Tenthoff says he remains a buyer of Eiger BioPharmaceuticals after the FDA agreed to a single, pivotal Phase III trial of Sarasar in 300 hepatitis delta virus patients. The stock is down year-to-date due to a Phase II pulmonary arterial hypertension failure, but Eiger remains the in a leadership position in HDV, Tenthoff tells investors in a research note. He reiterates an Overweight rating on the shares with a $17 price target.
01/03/18
LTCO
01/03/18
INITIATION
Target $32
LTCO
Buy
Eiger BioPharmaceuticals initiated with a Buy at Ladenburg
Ladenburg Thalmann started Eiger BioPharmaceuticals with a Buy rating and $32 price target.
CDNA CareDx
$8.72

0.19 (2.23%)

11/27/17
HCWC
11/27/17
INITIATION
Target $12
HCWC
Buy
CareDx initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Raghuram Selvaraju started CareDx with a Buy rating and $12 price target. The analyst believes non-invasive post-transplant surveillance tests reduce the use of biopsies and that favorable Medicare reimbursement "sets stage for success." CareDx;s AlloSure could drive test volume and revenue growth, Selvaraju contends.
09/26/17
PIPR
09/26/17
NO CHANGE
Target $7
PIPR
Overweight
Piper says CareDx story changed today, ups target to $7 from $3
Piper Jaffray analyst William Quirk raised his price target for CareDx to $7 from $3 after Molecular Diagnostics Services set the price for AlloSure at $2,840.75, well above his $1,500 forecast. CareDx in morning trading is up 30%, or $1.01, to 4.34. The analyst adds that Noridian, the Medicare Administrator Contractor who pays CareDx, will begin covering AlloSure on October 9. AlloSure's price is "much better than expectations and helps jump-start the company's move to profitability," Quirk tells investors in a research note. He believes the story for CareDx changed today and reiterates an Overweight rating on the shares.
09/27/17
RAJA
09/27/17
UPGRADE
Target $6.5
RAJA
Outperform
CareDx upgraded to Outperform from Market Perform at Raymond James
Raymond James analyst Nicholas Jansen upgraded CareDx to Outperform and established a $6.50 price target following positive reimbursement news by the CMS that offers a 14% increase in reimbursement to the core AlloMap test. Jansen sees significant growth in 2018 and 2019 now that the reimbursement picture is clear and AlloSure is set to launch soon and raised his 2018 revenue estimate to $62.2M, up 11%.
10/09/17
CHLM
10/09/17
NO CHANGE
Target $10
CHLM
Buy
CareDx price target raised to $10 from $4 at Craig-Hallum
Craig-Hallum analyst Kevin Ellich raised his price target for CareDX to $10 from $4, while reiterating a Buy rating on the shares as the recently completed equity offering should help bridge the gap as the company commercializes AlloSure. The analyst believes uptake of the company's non-invasive kidney transplant surveillance test will be solid leading to profitability in the next 12 months.
CNCE Concert Pharmaceuticals
$20.04

1.03 (5.42%)

01/16/18
MZHO
01/16/18
DOWNGRADE
Target $23
MZHO
Neutral
Concert Pharmaceuticals downgraded to Neutral from Buy at Mizuho
Mizuho downgraded Concert Pharmaceuticals (CNCE) to Neutral with a $23 price target after the Patent Trial and Appeal Board did not grant the company a Post Grant Review in the ongoing Patent '355 dispute with Incyte Pharma (INCY). While the firm believes this development has no implications for the ultimate outcome of the trial, it does mean the litigation overhang will remain in the foreseeable future. Further, Mizuho sees the stock as fairly valued.
03/09/18
MZHO
03/09/18
UPGRADE
Target $27
MZHO
Buy
Concert Pharmaceuticals upgraded to Buy from Neutral at Mizuho
Mizuho analyst Difei Yang upgraded Concert Pharmaceuticals to Buy and raised its price target to $27 from $23 citing the February 28 announcement the company would advance CTP-692, a new neuropsychiatric product candidate for treatment of schizophrenia. Yang believes the indication has significant potential to be differentiated from the current standard of care products by improving negative and cognitive symptoms.
03/02/18
HCWC
03/02/18
NO CHANGE
Target $25
HCWC
Buy
Concert Pharmaceuticals price target raised to $25 from $21 at H.C. Wainwright
H.C. Wainwright analyst Andrew Fein raised his price target for Concert Pharmaceuticals to $25 after the company discussed its newly unveiled compound, CTP-692, a deuterated form of D-serine for the treatment of schizophrenia. The this asset lands in the "sweet spot" of the company's core competency by leveraging its validated deuteration platform and in-house central nervous system expertise, Fein tells investors in a research note. He reiterates a Buy rating on the shares.
03/01/18
STFL
03/01/18
NO CHANGE
Target $27
STFL
Buy
Concert Pharmaceuticals selloff on shelf filing overdone, says Stifel
Stifel analyst Adam Walsh believes today's 16% selloff in Concert Pharmaceuticals shares is due to an "overreaction" to the company's filing of a $250M mixed shelf. He views the filing as a non-event, noting that the prior shelf was expiring and adding that he doesn't expect Concert to raise capital in the near-term as its current cash should be enough to fund the company into FY21. Walsh keeps a Buy rating and $27 price target on Concert shares.
AUPH Aurinia Pharmaceuticals
$5.16

0.01 (0.19%)

02/08/18
RBCM
02/08/18
INITIATION
Target $9
RBCM
Outperform
Aurinia Pharmaceuticals initiated with an Outperform at RBC Capital
RBC Capital analyst Douglas Miehm initiated Aurinia Pharmaceuticals with an Outperform rating and a price target of $9. The analyst says the stock represents an "attractive opportunity with upside" based on the Phase 3 study of its lupus nephritis drug voclosporin, which "has potential to become the first FDA-approved treatment for the disease".
03/16/18
CANT
03/16/18
NO CHANGE
Target $16
CANT
Overweight
Aurinia price target raised to $16 from $14 at Cantor Fitzgerald
Cantor Fitzgerald analyst Elemer Piros raised his price target for Aurinia Pharmaceuticals to $16 citing a reduction of the company's estimated tax rate to 21% from 35% following its Q4 results. Aurinia remains on track to enroll its Phase 3 Aurora study in Q4 and to initiate studies to advance its pipeline indications for voclosporin in Q2, Piros tells investors in a research note. He reiterates an Overweight rating on the shares.
10/30/17
HCWC
10/30/17
NO CHANGE
Target $12
HCWC
Buy
Aurinia Pharmaceuticals price target raised to $12 from $10 at H.C. Wainwright
H.C. Wainwright analyst Ed Arce raised his price target for Aurinia Pharmaceuticals to $12 after the company at its recent analyst day announced plans to expand voclosporin development to include focal segmental glomerulosclerosis and minimal change disease. The analyst maintains a Buy rating on the shares.
10/06/17
GHSC
10/06/17
INITIATION
Target $10
GHSC
Buy
Aurinia Pharmaceuticals initiated with a Buy at Seaport Global
Seaport Global analyst Vernon Bernardino initiated Aurinia Pharmaceuticals with a Buy and $10 price target. The analyst said Aurinia is focused on advancing voclosporin, an investigational drug that could be the first treatment specifically approved in the US for active lupus nephritis. Bernardino believes shares could be range-bound near-term, following recent strength, through the initial stage of the ongoing AURORA Phase III clinical trial.
GBT Global Blood Therapeutics
$43.80

2.15 (5.16%)

03/21/18
MSCO
03/21/18
DOWNGRADE
Target $61
MSCO
Equal Weight
Global Blood Therapeutics downgraded to Equal Weight at Morgan Stanley
As previously reported, Morgan Stanley analyst Matthew Harrison downgraded Global Blood Therapeutics to Equal Weight from Overweight as part of a rebalancing after a "strong run" for small-to-mid cap biotech stocks. While Harrison said he continues to expect positive Part A data for GBT-440, he also believes consensus expectations already reflect positive data. Harrison, who has a $61 price target on Global Blood shares, kept his model unchanged.
03/21/18
MSCO
03/21/18
DOWNGRADE
MSCO
Equal Weight
Global Blood Therapeutics downgraded to Equal Weight from Overweight at Morgan Stanley
03/21/18
03/21/18
DOWNGRADE
Target $87

Equal Weight
Sarepta downgraded as part of portfolio rebalancing at Morgan Stanley
As previously reported, Morgan Stanley analyst Matthew Harrison downgraded Sarepta (SRPT) to Equal Weight from Overweight as part of a rebalancing after a "strong run" for small-to-mid cap biotech stocks. He believes the next move higher in Sarepta will be driven by success in gene therapy, where he does not believe he has an edge in calling the outcome, Harrison tells investors. However, he also noted that initial signals from Sarepta's gene therapy program are promising with no safety issues and that his downgrade is not based on a specific concern around the program. He raised his price target on Sarepta shares to $87 from $64. Harrison also downgraded Loxo Oncology (LOXO) and Global Blood Therapeutics (GBT) as part of the rebalancing, citing valuation.
03/21/18
03/21/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Match Group (MTCH) downgraded to Neutral from Buy at Guggenheim. 2. Sarepta (SRPT), Global Blood Therapeutics (GBT), and Loxo Oncology (LOXO) were downgraded to Equal Weight from Overweight at Morgan Stanley. 3. Instructure (INST) downgraded to Buy from Strong Buy at Needham with analyst Scott Berg citing valuation, with the stock price having run up 133% since the start of 2017. 4. OncoCyte (OCX) downgraded to Neutral from Buy at Janney Capital. 5. Cboe Global Markets (CBOE) downgraded to Underweight from Neutral at JPMorgan with analyst Kenneth Worthington saying despite the stock market recovery, Cboe's risk/reward is skewed to the downside as pressure on the VIX futures is likely to continue. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
AVEO Aveo Oncology
$2.50

0.2 (8.70%)

10/06/17
GHSC
10/06/17
INITIATION
Target $7
GHSC
Buy
AVEO Oncology initiated with a Buy at Seaport Global
Seaport Global analyst Vernon Bernardino initiated AVEO Oncology with a Buy and $7 price target.
03/29/18
PIPR
03/29/18
NO CHANGE
Target $5
PIPR
Overweight
Aveo Oncology should be bought ahead of Phase III data, says Piper Jaffray
Piper Jaffray analyst Edward Tenthoff expects Aveo Oncology to report Phase III Tivo-3 data in third-line renal cell carcinoma in Q2. The analyst is confident tivozanib will achieve a statistically significant survival benefit over Nexavar and recommeds buying the stock ahead of the readout. Positive data will enable Aveo to respond to the 2013 tivozanib complete response letter with potential FDA approval in 2019, Tenthoff tells investors in a research note. He reiterates an Overweight rating on the shares with a $5 price target.
11/13/17
RILY
11/13/17
INITIATION
Target $5
RILY
Buy
Aveo Oncology initiated with a Buy at B. Riley FBR
B. Riley FBR analyst Madhu Kumar started Aveo Oncology with a Buy rating and $5 price target. The analyst sees the company's lead asset, vascular endothelial growth factor receptor tyrosine kinase inhibitor Fotivda, being successful in the pivotal Tivo-3 trial reading out in Q1 of 2018. He views the drug as undervalued.
11/13/17
11/13/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Party City (PRTY) assumed with an Overweight at JPMorgan. 2. MongoDB (MDB) was initiated with a Buy at Stifel and Canaccord, an Overweight at Barclays, an Equal Weight at Morgan Stanley, a Market Perform at JMP Securities, and a Neutral at Goldman Sachs. 3. Arista Networks (ANET) initiated with a Neutral at Piper Jaffray. 4. NetScout (NTCT) initiated with an Overweight at Piper Jaffray. 5. Aveo Oncology (AVEO) initiated with a Buy at B. Riley FBR. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
COLL Collegium Pharmaceutical
$21.79

-0.02 (-0.09%)

02/12/18
PIPR
02/12/18
NO CHANGE
Target $33
PIPR
Overweight
Piper reiterates Overweight on Collegium after Purdue stops marketing opioids
Piper Jaffray analyst David Amsellem reiterates an Overweight rating on Collegium Pharmaceutical with a $33 price target after Purdue Pharma announced that it will no longer promote its opioid products, including OxyContin. Purdue's actions will ultimately make it easier for Collegium to execute on securing additional contracts with payers where Xtampza ER has a position of formulary exclusivity, Amsellem tells investors in a research note.
02/12/18
JEFF
02/12/18
NO CHANGE
Target $32
JEFF
Buy
Collegium Pharmaceutical price target raised to $32 from $27 at Jefferies
Jefferies analyst David Steinberg raised his price target for Collegium Pharmaceutical to $32 saying IMS data show a "strong acceleration" for Xtampza in early 2018. Prescriptions las week increased 7.4% to 4,869, up 67% year-to-date, implying a $75M-plus run rate, Steinberg tells investors in a research note. In more good news for Collegium, Purdue announced this weekend that it will no longer detail OxyContin, the analyst adds. He raised his fiscal 2018 Xtampza sales estimate to $88M and keeps a Buy rating on the shares.
02/07/18
NEED
02/07/18
NO CHANGE
Target $35
NEED
Buy
Collegium Pharmaceutical price target raised to $35 from $28 at Needham
Needham analyst Serge Belanger raised his price target on Collegium Pharmaceutical to $35, citing a strong start to 2018 marked by the closing of the Nucynta licensing agreement and Xtampza Rx growth. Belanger says Nucynta is now being commercialized by the company and is expected to generate FY18 sales of $236M, while Xtampza's inclusion as the exclusive oxycodone ER on numerous prominent payor formularies should raise its FY18 sales to about $75M from prior view of $60M. Belanger keeps his Buy rating on Collegium Pharmaceutical.
03/08/18
HCWC
03/08/18
NO CHANGE
Target $33
HCWC
Buy
Collegium price target raised to $33 from $21 at H.C. Wainwright
H.C. Wainwright analyst Ed Arce raised his price target for Collegium Pharmaceutical to $33 following the company's Q4 results. Operational execution is driving continued strong growth of Xtampza ER, Arce tells investors in a post-earnings research note. The analyst sees "significant upside from current levels" and keeps a Buy rating on Collegium shares.
PDLI PDL BioPharma
$3.00

-0.02 (-0.66%)

10/26/17
COWN
10/26/17
NO CHANGE
Target $20
COWN
Outperform
Cowen views $20 per share as more reasonable offer for Neos
Cowen analyst Tyler Van Buren calls PDL BioPharma's (PDLI) $10.25 per share offer for Neos Therapeutics (NEOS) "unreasonably low." The analyst "wholeheartedly" agrees with the Neos board's rejection of the overture. Closer to $20 per share is a "more appropriate" offer, Van Buren tells investors in a research note after Neos disclosed the approach by PDL. He believes Neos shares will eventually reach $20, which also marks his price target, without or without a takeover. The analyst keeps an Outperform rating on the shares. The stock in morning trading is 38%, or $2.74, to $10.05.
10/26/17
JMPS
10/26/17
NO CHANGE
Target $30
JMPS
Outperform
PDL buyout offer for Neos a 'starting point at best,' says JMP Securities
JMP Securities analyst Jason Butler thinks PDL BioPharma's (PDLI) $10.25 per share takeover offer undervalues Neos Therapeutics (NEOS) and believes the company seeks to bring Neos to the negotiating table by making the offer public. Butler, who expects Neos to reject PDL's offer, believes an increased bid could be attractive to shareholders. He maintains an Outperform rating and $30 price target on Neos shares.
10/26/17
WELS
10/26/17
NO CHANGE
WELS
First offer to acquire Neos Therapeutics 'good, not great,' says Wells Fargo
Wells Fargo analyst David Maris notes that PDL BioPharma (PDLI) has announced a proposal to acquire Neos (NEOS) for $10.25 per share in cash. The analyst believes this offer is in the right neighborhood, even if a bit lower value than he thinks Neos deserves considering that since the initial offer was made, Neos has received approval for Adzenys XR liquid, launched Cotempla XR-ODT, and reached a paragraph IV settlement on Adzenys XR-ODT. Maris believes that the offer will result in Neos being acquired for $10.25 or higher, but he thinks that there may be a value-enhancing opportunity should Neos' products end up in a larger company's established CNS portfolio, the benefits PDL specifically offers, considering its lack of manufacturing, regulatory, commercial or reimbursement expertise in CNS, is not immediately apparent to him.

TODAY'S FREE FLY STORIES

KORS

Michael Kors

$68.63

0.25 (0.37%)

, LULU

Lululemon

$106.18

-0.19 (-0.18%)

11:07
05/26/18
05/26
11:07
05/26/18
11:07
Periodicals
Dollar Tree looks interesting, Barron's says »

Next week, another 20…

KORS

Michael Kors

$68.63

0.25 (0.37%)

LULU

Lululemon

$106.18

-0.19 (-0.18%)

GME

GameStop

$12.64

-0.1 (-0.78%)

DLTR

Dollar Tree

$95.23

0.59 (0.62%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    May

  • 31

    May

  • 31

    May

  • 31

    May

  • 12

    Jun

  • 14

    Jun

  • 26

    Jun

KHC

Kraft Heinz

$57.78

0.72 (1.26%)

, QCOM

Qualcomm

$59.95

0.85 (1.44%)

10:58
05/26/18
05/26
10:58
05/26/18
10:58
Periodicals
Kraft Heinz, J&J among safe, 'solid' dividend stocks, Barron's says »

Kraft Heinz (KHC),…

KHC

Kraft Heinz

$57.78

0.72 (1.26%)

QCOM

Qualcomm

$59.95

0.85 (1.44%)

MRK

Merck

$59.08

-0.03 (-0.05%)

TGT

Target

$71.22

0.28 (0.39%)

OMC

Omnicom

$71.98

-0.1 (-0.14%)

CCL

Carnival

$64.27

0.12 (0.19%)

JNJ

Johnson & Johnson

$121.40

0.06 (0.05%)

MMM

3M

$198.98

-0.38 (-0.19%)

LLY

Eli Lilly

$82.75

0.05 (0.06%)

VLO

Valero

$118.81

-3.06 (-2.51%)

EMR

Emerson

$72.50

-0.77 (-1.05%)

WBA

Walgreens Boots Alliance

$63.52

0.09 (0.14%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

  • 30

    May

  • 30

    May

  • 02

    Jun

  • 04

    Jun

  • 05

    Jun

  • 05

    Jun

  • 06

    Jun

  • 07

    Jun

  • 12

    Jun

  • 19

    Jun

  • 10

    Sep

  • 23

    Oct

MU

Micron

$61.33

-0.15 (-0.24%)

10:48
05/26/18
05/26
10:48
05/26/18
10:48
Periodicals
Micron can solve low valuation, Barron's says »

Micron's stock…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    May

  • 20

    Jun

ATUS

Altice USA

$18.50

-0.05 (-0.27%)

10:40
05/26/18
05/26
10:40
05/26/18
10:40
Periodicals
Altice's spinoff could be winning bet, Barron's says »

On June 8, Altice will…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

  • 30

    May

MU

Micron

$61.33

-0.15 (-0.24%)

, XLNX

Xilinx

$69.63

0.88 (1.28%)

10:35
05/26/18
05/26
10:35
05/26/18
10:35
Periodicals
AI revolution just getting started, Barron's says »

Artificial Intelligence…

MU

Micron

$61.33

-0.15 (-0.24%)

XLNX

Xilinx

$69.63

0.88 (1.28%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    May

  • 20

    Jun

ZTCOY

ZTE Corp.

$0.00

(0.00%)

, DDAIF

Daimler AG

$0.00

(0.00%)

08:08
05/26/18
05/26
08:08
05/26/18
08:08
Hot Stocks
Week in review: How Trump's policies moved stocks »

Catch up on the top…

ZTCOY

ZTE Corp.

$0.00

(0.00%)

DDAIF

Daimler AG

$0.00

(0.00%)

FCAU

Fiat Chrysler

$21.82

-0.445 (-2.00%)

HMC

Honda

$32.04

-0.34 (-1.05%)

NSANY

Nissan

$0.00

(0.00%)

F

Ford

$11.51

-0.11 (-0.95%)

GM

General Motors

$38.30

-0.09 (-0.23%)

TM

Toyota

$129.97

-2.47 (-1.87%)

VLKAY

Volkswagen

$0.00

(0.00%)

BAC

Bank of America

$30.16

-0.03 (-0.10%)

C

Citi

$68.42

-0.86 (-1.24%)

GS

Goldman Sachs

$235.05

-1.1 (-0.47%)

JPM

JPMorgan

$110.62

-0.64 (-0.58%)

MS

Morgan Stanley

$53.02

-0.96 (-1.78%)

USB

U.S. Bancorp

$50.54

-0.14 (-0.28%)

WFC

Wells Fargo

$54.91

0.25 (0.46%)

TWTR

Twitter

$33.64

0.11 (0.33%)

AA

Alcoa

$47.92

-1.26 (-2.56%)

CENX

Century Aluminum

$16.27

-0.07 (-0.43%)

AOBC

American Outdoor Brands

$12.53

0.05 (0.40%)

RGR

Sturm, Ruger

$63.10

0.5 (0.80%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    May

  • 30

    May

  • 01

    Jun

  • 06

    Jun

  • 20

    Jun

  • 22

    Jun

  • 13

    Jul

  • 27

    Jul

  • 10

    Sep

  • 12

    Oct

  • 14

    Jan

  • 15

    Apr

  • 15

    Jul

  • 15

    Oct

HCLP

Hi-Crush Partners

$13.20

-0.825 (-5.88%)

17:54
05/25/18
05/25
17:54
05/25/18
17:54
Hot Stocks
Hi-Crush Partners provides update on bulldozer incident in Whitehall facility »

Hi-Crush Partners…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

POST

Post Holdings

$77.98

1.49 (1.95%)

17:37
05/25/18
05/25
17:37
05/25/18
17:37
Hot Stocks
Post Holdings reports fire in Michael Foods' plant in Pennsylvania »

Post Holdings reported a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Jun

ABMD

Abiomed

$394.49

0.04 (0.01%)

, WYN

Wyndham

$107.98

-0.58 (-0.53%)

17:34
05/25/18
05/25
17:34
05/25/18
17:34
Hot Stocks
Abiomed to enter S&P 500 index on May 31 »

S&P MidCap 400…

ABMD

Abiomed

$394.49

0.04 (0.01%)

WYN

Wyndham

$107.98

-0.58 (-0.53%)

MSCC

Microsemi

$68.74

0.005 (0.01%)

PRAH

PRA Health

$81.19

0.33 (0.41%)

GME

GameStop

$12.64

-0.1 (-0.78%)

FRED

Fred's

$1.69

0.05 (3.05%)

PRSP

Symbol now PB

$0.00

(0.00%)

RRTS

Roadrunner

$2.19

0.04 (1.86%)

DXC

DXC Technology

$94.20

-5.42 (-5.44%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    May

  • 31

    May

  • 05

    Jun

  • 12

    Jun

PRAH

PRA Health

$81.19

0.33 (0.41%)

, ABMD

Abiomed

$394.49

0.04 (0.01%)

17:24
05/25/18
05/25
17:24
05/25/18
17:24
Hot Stocks
Breaking Hot Stocks news story on PRA Health, Abiomed »

PRA Health to replace…

PRAH

PRA Health

$81.19

0.33 (0.41%)

ABMD

Abiomed

$394.49

0.04 (0.01%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    May

  • 05

    Jun

  • 12

    Jun

WYN

Wyndham

$107.98

-0.58 (-0.53%)

, MSCC

Microsemi

$68.74

0.005 (0.01%)

17:23
05/25/18
05/25
17:23
05/25/18
17:23
Hot Stocks
Breaking Hot Stocks news story on Wyndham, Microsemi »

Wyndham to replace…

WYN

Wyndham

$107.98

-0.58 (-0.53%)

MSCC

Microsemi

$68.74

0.005 (0.01%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ABMD

Abiomed

$394.49

0.04 (0.01%)

, WYN

Wyndham

$107.98

-0.58 (-0.53%)

17:21
05/25/18
05/25
17:21
05/25/18
17:21
Hot Stocks
Breaking Hot Stocks news story on Abiomed, Wyndham »

ABIOMED to replace…

ABMD

Abiomed

$394.49

0.04 (0.01%)

WYN

Wyndham

$107.98

-0.58 (-0.53%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    May

  • 05

    Jun

  • 12

    Jun

PCG

PG&E

$44.67

0.84 (1.92%)

17:16
05/25/18
05/25
17:16
05/25/18
17:16
Periodicals
CA Forestry Dept rules PG&E equipment responsible for wildfires, Bloomberg says »

Report filed by…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FARM

Farmer Bros.

$28.50

0.15 (0.53%)

17:09
05/25/18
05/25
17:09
05/25/18
17:09
Hot Stocks
Levin Capital Strategies reports 8.4% stake in Farmer Bros »

Levin Capital purchased…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NDLS

Noodles & Company

$8.90

-0.35 (-3.78%)

17:07
05/25/18
05/25
17:07
05/25/18
17:07
Syndicate
Breaking Syndicate news story on Noodles & Company »

Noodles & Company…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WIN

Windstream

$1.22

-0.125 (-9.29%)

17:06
05/25/18
05/25
17:06
05/25/18
17:06
Hot Stocks
Windstream completes one-for-five reverse stock split »

Windstream completed its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NDLS

Noodles & Company

$8.90

-0.35 (-3.78%)

17:06
05/25/18
05/25
17:06
05/25/18
17:06
Syndicate
Breaking Syndicate news story on Noodles & Company »

Noodles & Company…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EPD

Enterprise Products

$27.87

-0.12 (-0.43%)

17:01
05/25/18
05/25
17:01
05/25/18
17:01
Hot Stocks
Enterprise Products conduts open season for West Texas Crude oil expansion »

Enterprise Products…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INO

Inovio

$4.89

0.06 (1.24%)

16:37
05/25/18
05/25
16:37
05/25/18
16:37
Syndicate
Breaking Syndicate news story on Inovio »

Inovio files $250M mixed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RCII

Rent-A-Center

$10.14

0.13 (1.30%)

16:36
05/25/18
05/25
16:36
05/25/18
16:36
Hot Stocks
Rent-A-Center 16.8% shareholder Engaged Capital nominates Carol McFate to Board »

On May 25, 2018, Engaged…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AKER

Akers Biosciences

$0.59

0.0086 (1.48%)

16:34
05/25/18
05/25
16:34
05/25/18
16:34
Hot Stocks
Akers Biosciences receives delinquency notice from NASDAQ »

Akers Biosciences…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DHCP

Ditech

$6.60

0.37 (5.94%)

16:31
05/25/18
05/25
16:31
05/25/18
16:31
Hot Stocks
Ditech discloses receipt of late filing notice from NYSE »

Ditech Holding announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GPS

Gap

$28.15

-4.82 (-14.62%)

, FL

Foot Locker

$55.97

9.585 (20.67%)

16:30
05/25/18
05/25
16:30
05/25/18
16:30
General news
On The Fly: Top stock stories for Friday »

Stocks on Wall Street…

GPS

Gap

$28.15

-4.82 (-14.62%)

FL

Foot Locker

$55.97

9.585 (20.67%)

HLF

Herbalife Nutrition

$48.76

-5.09 (-9.45%)

IEP

Icahn Enterprises

$69.41

0.22 (0.32%)

FCAU

Fiat Chrysler

$21.82

-0.445 (-2.00%)

DGX

Quest Diagnostics

$105.89

5 (4.96%)

UNH

UnitedHealth

$244.96

2.23 (0.92%)

ROST

Ross Stores

$77.35

-5.6 (-6.75%)

ADSK

Autodesk

$132.80

-5.96 (-4.30%)

AAL

American Airlines

$44.89

1.34 (3.08%)

LUV

Southwest

$52.86

1.65 (3.22%)

DAL

Delta Air Lines

$55.89

1.48 (2.72%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    May

  • 30

    May

  • 30

    May

  • 12

    Jun

  • 13

    Jun

  • 14

    Jun

  • 26

    Jun

  • 29

    Jun

16:30
05/25/18
05/25
16:30
05/25/18
16:30
Options
Preliminary option volume of 16.4M today »

Preliminary option volume…

VTL

Vital Therapies

$5.65

-0.475 (-7.76%)

16:26
05/25/18
05/25
16:26
05/25/18
16:26
Syndicate
Breaking Syndicate news story on Vital Therapies »

Vital Therapies files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Jun

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.